CCCC

C4 Therapeutics, Inc.

• Dow Jones·1d ago

  C4 Therapeutics Initiated at Overweight by JP Morgan

• Dow Jones·1d ago

  C4 Therapeutics Price Target Announced at $10.00/Share by JP Morgan

• TipRanks·1d ago

  C4 Therapeutics initiated with an Overweight at JPMorgan

• Seeking Alpha·10/03 15:00

  PepsiCo, Delta Lead Upcoming Earnings Slate; Fed Minutes In Focus

• Seeking Alpha·10/02 19:00

  Catalyst Watch: Microsoft event, FOMC talk, and the finish line for Paramount-Warner Bros.

• Seeking Alpha·10/02 14:15

  Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026

• NASDAQ·09/25 15:07

  Cemsidomide Shows Immune Activation In C4 Therapeutics' Myeloma Study

• TipRanks·09/25 11:27

  C4 Therapeutics Reports New Cemsidomide Myeloma Data

• TipRanks·09/25 11:10

  C4 Therapeutics presents biomarker data from Phase 1 trial of cemsidomide

• Benzinga·09/25 11:02

  C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting

• Seeking Alpha·09/05 07:54

  C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts

• Benzinga·09/03 11:10

  C4 Therapeutics To Present New Biomarker Data On Immunomodulatory Effects Of Cemsidomide In Combination With Dexamethasone From Phase 1 Trial For RRMM At IMS Annual Meeting

• NASDAQ·08/21 16:00

  Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

• Simply Wall St·08/14 12:03

  Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

• NASDAQ·08/13 15:13

  C4 Therapeutics Narrows Loss In Q2; Phase 2 Trial's ORR Data Due In H2 FY27